Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effect of Sulfasalazine on CRH Levels in Pregnant Women
Sponsor: Rutgers, The State University of New Jersey
Summary
The goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are: * Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a prior history of preterm birth? * Does sulfasalazine reduce the incidence of recurrent preterm birth in pregnant persons given drug vs. controls? Consenting participants will be randomized to receive sulfasalazine or to a control group and will undergo serial blood draws to assess plasma CRH levels.
Official title: The Effect of Sulfasalazine on CRH Levels in Pregnant Women With a History of Pre-Term Birth: A Randomized Controlled Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-03-01
Completion Date
2026-06-30
Last Updated
2025-09-22
Healthy Volunteers
Yes
Conditions
Interventions
Sulfasalazine
Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
Locations (1)
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States